Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Almirall S.A., Ronda General Mitre, 151, 08022 Barcelona, Spain
Meptid tablets are indicated for the short term treatment of moderate pain.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with meptazinol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
200 mg 3 to 6 hourly as required. Usually 1 tablet 4 hourly.
The adult dosage schedule may be used in the elderly.
No data are available.
Meptid tablets are subject to hepatic first pass metabolism which prevents systemic concentration of the drug reaching levels achieved by parenteral administration.
Recommended treatment includes gastric lavage, supportive therapy and naloxone if required.
In the unlikely event of overdose producing respiratory depression, naloxone is the treatment of choice. Naloxone has a short duration of action in comparison with meptazinol. Repeated administration or administration by continuous intravenous infusion may be considered necessary. The effects are only partially reversed by naloxone.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
3 years.
Store below 25°C.
Cartons containing PVC blister packs of 6, 28, 56, 100 or 112 tablets.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
